Eli Lilly and Company (LLY)vsPsyence Biomedical Ltd. Common Shares (PBM)
LLY
Eli Lilly and Company
$1,131.42
-0.32%
HEALTHCARE · Cap: $948.95B
PBM
Psyence Biomedical Ltd. Common Shares
$3.69
-6.58%
HEALTHCARE · Cap: $7.64M
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
PBM
Avoid26
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : PBM
The strongest argument for PBM centers on Price/Book.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : PBM
The primary concerns for PBM are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while PBM is a value play — different risk/reward profiles.
PBM carries more volatility with a beta of 1.65 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 26/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Psyence Biomedical Ltd. Common Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Psyence Biomedical Ltd. (PBM) is a cutting-edge biotechnology firm focused on harnessing the therapeutic potential of psychedelic compounds to transform mental health and wellness treatments. Through its vertically integrated model, the company excels in the cultivation, formulation, and clinical research of psilocybin and other psychedelics, aiming to develop novel therapies that meet the pressing needs of patients. With a robust intellectual property portfolio and a promising clinical pipeline, Psyence is strategically positioned to leverage the increasing acceptance of psychedelics in the healthcare landscape, addressing urgent mental health challenges with innovative and effective solutions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?